Medicilon assists Shijiazhuang No.4 Pharmaceutical's Class 1 new chemical drug SYN045 tablets obtain clinical approval

On January 26, SYN045, a Class I new drug developed by Shijiazhuang No.4 Pharmaceutical, received a clinical trial approval notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This marks another substantial step forward in the research and development of the company's second innovative drug.

Shanghai Medicilon Inc. (Medicilon), as a partner of Shijiazhuang No.4 Pharmaceutical, provided preclinical research services such as pharmacokinetics and safety evaluation for the development of SYN045 tablets, helping to successfully obtain approval.

SYN045 is a Class I new drug independently developed by Shijiazhuang No.4 Pharmaceutical. SYN045 is a selective long-acting PGI2 receptor agonist and is intended to be used for pulmonary arterial hypertension. Preclinical studies have shown that SYN045 has good target selectivity, compound activity, and safety.

Currently, Medicilon's preclinical research service platform has established a research operation process and quality system that complies with international standards and has a laboratory of 29,000 square meters. Medicilon has also obtained NMPA drug GLP laboratory certification qualification and complies with the GLP laboratory standards of the US FDA, Australian TGA, and EU EMEA. The animal experiment facility has passed the International Laboratory Animal Assessment and Accreditation (AAALAC) and can simultaneously raise non-human primates, dogs, rats, rabbits, guinea pigs, mini pigs and other experimental animals, and can provide services such as pharmacological efficacy, pharmacokinetic research and safety evaluation.

About Shijiazhuang No.4 Pharmaceutical

Shijiazhuang No.4 Pharmaceutical is a large-scale high-tech pharmaceutical enterprise that develops collaboratively with R&D and industrialization in multiple fields of the industry chain including innovative drugs, generic drugs, specialty APIs, high-end preparations and pharmaceutical packaging materials. Shijiazhuang No.4 Pharmaceutical ranks among the top 100 enterprises in China's pharmaceutical industry and among the outstanding brand enterprises exporting preparations in China's chemical and pharmaceutical industry. In 2007, the company was listed on the HKEX (SSY Group 02005.HK).

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. By the end of June 2023, Medicilon has provided new drug R&D services to more than 2,000 clients around the world, and participated in the R&D of 420 new drug projects that have been approved for clinical trials. Medicilon is proud to contribute to human health in the globe.

In Vitro Enzyme Activity Assay

Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+ in vitro enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

阅读全文

Fluorescence Probes Synthesis

Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. Design and synthesis steps Fluorescent probes are tools used to detect, measure and analyze biomolecules, cells and tissues. They achieve these purposes by emitting and receiving fluorescent signals. Medicilon can complete the design and synthesis of fluorescent probes for biomolecules. Selection of target molecules and determination of target. Selection of fluorescent dyes. Design of molecular structure. Synthesize probe molecules. Testing the properties of probe molecules. Custom synthesis Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. After years of development, Medicilon's fluorescent probes and labeling platforms have accumulated rich experience...

阅读全文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

阅读全文

Shanghai Medicilon Inc.

搜索此博客